share_log
Moomoo 24/7 ·  04/15 08:50

Organovo Shares Are Trading Higher After the Company Announced Phase 2 Results for FXR314. Study Results Demonstrated Statistically Significant Reduction in Liver Fat Content From Baseline in Patients Receiving FXR314 Compared to Placebo

Organovo公佈 FXR314 第二階段業績後,該公司股價走高。研究結果表明,與安慰劑相比,接受 FXR314 的患者的肝脂含量比基線顯著降低

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論